Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,23782587,maximum inhibition,The percentage of DPP-4 inhibition by vildagliptin remained unchanged when vildagliptin was given alone or co-administered with voglibose; maximum inhibition was 98.3 ± 1.4% (mean ± SD) for vildagliptin alone and 97.4 ± 1.1% with co-administration.,Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23782587/),%,98.3,17286,DB04878,Voglibose
,23782587,maximum inhibition,The percentage of DPP-4 inhibition by vildagliptin remained unchanged when vildagliptin was given alone or co-administered with voglibose; maximum inhibition was 98.3 ± 1.4% (mean ± SD) for vildagliptin alone and 97.4 ± 1.1% with co-administration.,Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes. ,Ki-Q11,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23782587/),%,97.4,17287,DB04878,Voglibose
,17171777,limit of detection,The assay was linear over the range 5.00-2000 ng/mL with a limit of detection of 1.00 ng/mL.,Determination of miglitol in human plasma by liquid chromatography/tandem mass spectrometry. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17171777/),[ng] / [ml],1.00,92848,DB04878,Voglibose
